Vivriti Group, a mid-market focussed financial services group, has announced the establishment of Vivriti Next, a new operating and holding company designed to consolidate the Group’s businesses and accelerate future growth. “This reorganisation will bring the lending business of Vivriti Capital and the private credit asset management business of Vivriti Asset Management under a unified platform,” the Group said. “Under Vivriti Next, the Group will offer a new services for mid-market enterprises, including capital markets, technology solutions, and advisory on capital structuring, financing, risk, ratings, and ESG,” it added. Now equity shareholders of Vivriti Capital will transition to the new holding company structure, maintaining a similar diversified and institution-led cap-table. Vineet Sukumar, Founder and Managing Director, Vivriti Next, has committed an equity investment of Rs 200 crore in his personal capacity to Vivriti Next. With this, the Group has raised promoter and external capital of Rs 1,630 crore of equity from founders and prominent investors – Creation Investments, Lightrock, and TVS Capital Funds. “As our mid-market clients have scaled over the years, their needs have moved well beyond standalone borrowing to strategic solutions. They are navigating capital markets access, balance sheet structuring, ESG & risk management, and technology-led efficiency—all at the same time,” Mr. Sukumar said. “Vivriti Next has been created as a platform to respond to this complexity by building new business models in how we support our clients beyond lending. Vivriti Next will now sit front and centre of the Vivriti Group’s next phase—driving growth, profitability and capital efficiency across businesses,” he said. “It will also play a critical role in shaping group strategy and supporting future capital raising efforts as Vivriti continues to scale its platform,” he added. Published – February 24, 2026 11:49 pm IST Share this: Click to share on WhatsApp (Opens in new window) WhatsApp Click to share on Facebook (Opens in new window) Facebook Click to share on Threads (Opens in new window) Threads Click to share on X (Opens in new window) X Click to share on Telegram (Opens in new window) Telegram Click to share on LinkedIn (Opens in new window) LinkedIn Click to share on Pinterest (Opens in new window) Pinterest Click to email a link to a friend (Opens in new window) Email More Click to print (Opens in new window) Print Click to share on Reddit (Opens in new window) Reddit Click to share on Tumblr (Opens in new window) Tumblr Click to share on Pocket (Opens in new window) Pocket Click to share on Mastodon (Opens in new window) Mastodon Click to share on Nextdoor (Opens in new window) Nextdoor Click to share on Bluesky (Opens in new window) Bluesky Like this:Like Loading... Post navigation Alembic Pharma gets U.S. FDA nod for generic antifungal drug AI’s positives outweigh human and climate impact: NASSCOM